Exelixis Eyes Oncology Deals, Readies Zanzalintinib Launch as Cabozantinib Tops $3BMarketBeat • 09/17/26
Exelixis, Inc. (EXEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/15/26
Exelixis Eyes CABOMETYX Growth, Zanzalintinib Catalysts Across Cancer FranchisesMarketBeat • 09/14/26
Exelixis, Inc. (EXEL) Presents at Citigroup's Biopharma Back to School Summit 2026 TranscriptSeeking Alpha • 09/09/26
Exelixis, Inc. (EXEL) Presents at Wells Fargo 21st Annual Healthcare Conference TranscriptSeeking Alpha • 09/08/26
Exelixis (EXEL) Up 13.3% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 09/04/26
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in SeptemberBusiness Wire • 09/01/26
Exelixis: "Hold" On Zanzalintinib Subpopulation Miss And STELLAR-304 2H 2026 DataSeeking Alpha • 09/01/26
Exelixis Announces Update on Patent Litigation Trial Appeal with MSN LaboratoriesBusiness Wire • 08/31/26
EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with SBS LawBusiness Wire • 08/16/26
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Exelixis (EXEL)GlobeNewsWire • 08/13/26